Sitagliptin + Metformin HClThird Party Manufacturing in India

Sitagliptin + Metformin HCl works by combining two distinct, complementary anti-hyperglycemic pathways. Sitagliptin inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme to extend active incretin hormone levels, which increases insulin release and reduces glucagon secretion. Metformin hydrochloride lowers hepatic glucose production, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity. Unlike monotherapies, this combination targets multiple core pathophysiological defects of type 2 diabetes. It is highly effective and well-tolerated for long-term glycemic control.

Therapeutic Uses

• Type 2 Diabetes Mellitus: Serves as a first-line combination therapy to improve glycemic control when monotherapy is insufficient.
• HbA1c Reduction: Lowers both fasting and postprandial plasma glucose levels to reduce long-term cardiovascular risks.
• Insulin Secretion Optimization: Supports natural pancreatic endocrine responses to dietary glucose loads.

Why Manufacturers Choose Sitagliptin + Metformin HCl

This combination is a market leader in chronic diabetes care, offering stable, high-volume revenue potential. Selecting Sitagliptin + Metformin HCl third party manufacturing in India through Celesta gives you access to advanced high-capacity blending and tableting technologies. Our partner facilities process premium CAS 486460-32-6 combinations under strict WHO-GMP validation. Their adherence to WHO-GMP guidelines ensures uniform distribution of low-dose sitagliptin alongside high-dose metformin across all batches.